Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HR20013 with Dexamethasone in Solid Tumors
NCT05465681Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fosrolapitant and palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time 0 to Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity and 3 more. Started Aug 2022; status: completed.
02
Drugs
fosrolapitantpalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT05465681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05465681.